Its especially helpful for those who have struggled with obesity or feel stuck after trying fad diets, lifestyle modifications, or regular exercise alone
We also used a self-controlled case series design [19], which comprised of new users of GLP-1 RAs ( n = 85,717 ) or SGLT-2 inhibitors ( n = 78,366 ) or DPP-4 inhibitors ( n = 35,762) from 2014 to 2022
At the same time, side effects are often part of the equation when using GLP-1s for weight loss
Compounding pharmacies for semaglutide cause concern
While Ozempic is approved for diabetes, the FDA has approved semaglutide under a different brand name, Wegovy, specifically for chronic weight management
Understanding whether a patient experiences altered sensory perception, reduced food enjoyment, or lower motivation toward food may support more individualized dietary guidance and improve communication between patients and healthcare providers